In a turn of events that resonates like a modern-day David vs. Goliath story, Pfizer Inc., the pharmaceutical giant, has consented to pay a whopping $50 million. This move seeks to conclude claims suggesting that both Pfizer and Mylan Pharmaceuticals manipulated emergency allergy medication prices, a tale entangled in years of court battles and extended deliberation periods. This decisive action emerged from a motion filed in the heartland state’s federal court – Kansas.
Pfizer $50m Epipen Settlement : A Victory for the Buyers?
Labeling Pfizer’s settlement as an “outstanding outcome,” EpiPen consumers, who were previously grappling with the district court’s dismissal of their grievances, expressed their relief and optimism. They fervently argued, “Had there been no merit in our claims against Pfizer, we wouldn’t have passionately pursued them.” Yet, the impending threat of prolonged court wrangling was never far from their minds.
Casting a wider net, they implored the court to recognize a nationwide settlement class, encompassing every individual or entity that bought EpiPens or their generic counterparts from Mylan or Teva, targeting resales from March 2014 till the dispute’s resolution. This vast network consists of 74 members, spread as wide as the American landscape.
